Join us at the SABCS 2022, as we announce the results from our First-in-Human Expansion Study of PMD-026 in Metastatic Triple-Negative Breast Cancer (TNBC) Patients. Our results highlighted that PMD-026 doubled progression free survival in metastatic TNBC patients relative to chemotherapy with a well-tolerated safety profile.
Back to All Events
Earlier Event: November 5
Forbes 50 over 50 Executive Event Featuring a Conversation with First Lady Jill Biden and Mika Brzezinski
Later Event: April 8
American Association for Cancer Research